• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

NUTLIN-3 Drug Record

  • Summary
  • Interactions
  • Claims
  • NUTLIN-3 chembl:CHEMBL191334

    Alternate Names:

    NUTLIN-3

    Drug Info:

    (0 More Sources)

    Publications:

    Yu S et al., 2009, Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction., J Med Chem
    Ribeiro CJ et al., 2014, Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents., Bioorg Med Chem
    Davidovich P et al., 2015, Discovery of Novel Isatin-Based p53 Inducers., ACS Med Chem Lett
    Gomez-Monterrey I et al., 2010, Identification of the spiro(oxindole-3,3'-thiazolidine)-based derivatives as potential p53 activity modulators., J Med Chem
    Tonsing-Carter et al., 2015, Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model., Mol. Cancer Ther.
    Carrillo et al., 2015, Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells., Mol. Cancer Res.
    Karan et al., 2016, Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53., Mol. Cancer Ther.
    Hardcastle IR et al., 2011, Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency., J Med Chem
    Vassilev LT et al., 2004, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2., Science
  • NUTLIN-3   MDM2

    Interaction Score: 13.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21314128 19928922 24268795 21058726 14704432


    Sources:
    DTC PharmGKB

  • NUTLIN-3   TP53

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy CTX-1 + Nutlin-3
    Indication/Tumor Type acute myeloid leukemia
    Response Type sensitive

    PMIDs:
    19928922 24268795 26288684 21058726 26494859 25964101 26883273


    Sources:
    DTC JAX-CKB

  • DTC: NUTLIN-3

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL191334 ChEMBL Drug ID

    Drug Info:

    Publications:
    Gomez-Monterrey I et al., 2010, Identification of the spiro(oxindole-3,3'-thiazolidine)-based derivatives as potential p53 activity modulators., J Med Chem
    Hardcastle IR et al., 2011, Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency., J Med Chem
    Ribeiro CJ et al., 2014, Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents., Bioorg Med Chem

  • PharmGKB: nutlin-3

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Vassilev LT et al., 2004, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2., Science

  • JAX-CKB: Nutlin-3

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Carrillo et al., 2015, Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells., Mol. Cancer Res.
    Tonsing-Carter et al., 2015, Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model., Mol. Cancer Ther.
    Karan et al., 2016, Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53., Mol. Cancer Ther.

  • ChemblDrugs: chembl:CHEMBL191334

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21